Overview

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if Darbepoetin alfa is effective in treating low red blood cell levels after allogeneic stem cell transplant. Darbepoetin alfa has been shown to help raise red blood cell levels without blood transfusions.
Phase:
N/A
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Amgen
Brigham and Women's Hospital
Treatments:
Darbepoetin alfa